Table 2:
Characteristics* | 0 to <7 yrs, n=524 | ≥7 to <13 yrs, n=1354 | ≥13 to ≤18 yrs, n=1672 |
---|---|---|---|
Systolic BP percentile | 76 [50, 91] | 67 [38, 89] | 52 [24, 76] |
Systolic BP status | |||
<90th percentile | 71% (374) | 77% (1037) | 87% (1457) |
≥90th to <95th percentile | 10% (50) | 8% (106) | 5% (89) |
≥95th percentile | 19% (100) | 15% (211) | 8% (126) |
Diastolic BP percentile | 82 [60, 94] | 65 [44, 86] | 57 [31, 82] |
Diastolic BP status | |||
<90th percentile | 64% (336) | 80% (1078) | 84% (1403) |
≥90th to <95th percentile | 13% (66) | 7% (99) | 6% (96) |
≥95th percentile | 23% (122) | 13% (177) | 10% (173) |
Blood pressure status | |||
Normal | 54% (282) | 67% (909) | 73% (1219) |
Elevated | 14% (76) | 11% (151) | 11% (189) |
Stage 1 hypertensive BP | 28% (144) | 18% (246) | 12% (199) |
Stage 2 hypertensive BP | 4% (21) | 4% (48) | 4% (65) |
Hypertensive BP (stages 1 & 2) | 32% (166) | 22% (294) | 16% (264) |
Current use of antihypertensive medication | 45% (234) | 65% (878) | 72% (1201) |
Current use of ACEi/ARB | 31% (162) | 55% (748) | 61% (1023) |
Self-reported hypertension | 32% (165) | 46% (624) | 47% (783) |
Reported as median [IQR] for continuous variables and percent (n) for categorical variables. ACEi angiotensin-converting enzyme inhibitor, ARB angiotensin receptor blocker.